Rising chronic diseases to augment the Western Blotting Market Growth

 

Western Blotting Market

Western Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics, Others) End Users (Academia and Research Institutes, Diagnostic Centers, Others), and by Region (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030

The global Western Blotting Market is estimated to be valued at US$ 759.5 million in 2023 and is expected to exhibit a CAGR of 6.8 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Western Blotting is a vastly utilized analytical method in molecular biology to detect particular proteins from a specimen of tissue homogenate or derivatives. It includes three main steps; protein separation depending upon molecular weight, transmission of detached proteins to a membrane and identification of the proteins with the support of antibodies. Western Blotting is a main tool in fundamental and developed research survey such as detection of post-translational changes, identification of protein-protein relations, protein-DNA relations, disease analysis and several others. The initial procedure in the Western Blotting is protein parting which is attained by gel electrophoresis.

Competitive Landscape:

Key players involved in the growth of global western blotting market are Biorad laboratories, Perklin Elmer, Danaher Corporation (Cytiva), Thermofisher Scientific, and Merck & Co.

Market Key Drivers:

Rising prevalence of chronic diseases such as heart disease, cancer and diabetes is expected to augment the growth of global western blotting market. For instance, as per NIH around one in three adults suffer from multiple chronic diseases across the globe.

Increasing developments and initiatives in the blotting technique is projected to propel the growth of the global western blotting market. For instance, For Lyme Disease, the USFDA has advised the two-tier protocol utilizing an ELISA test primarily and further the précised western blot tests for the assurance of diagnosis if the outcomes of ELISA are positive.

Covid-19 Impact Analysis:

COVID-19 had a significant impact on the western blotting market owing to the unexpected spread. For instance, as per the article printed in 2020 under the title ‘COVID-19 for diagnostic purposes and for  assessing the immunity, combining serologic test, that consists Western blots, along with skin testing utilizes SARS-CoV-2 antigens for evaluating DTH reactions, was probably advantageous. 

Key Takeaways:

The global Western blotting market is anticipated to exhibit a CAGR of 8.3 % during the forecast period rising HIV and AIDS. For instance, as per Global HIV & AIDS statistics, 38.4 million people across the globe were living with HIV in 2021.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in the global Western blotting market due to mergers and acquisitions, product expansions and rising chronic diseases, increasing healthcare infrastructure, For instance, as per CDC one in six adults suffer from chronic diseases in U.S.